𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Soluble Fas and Fas ligand in HIV/HCV coinfected patients and impact of HCV therapy

✍ Scribed by M. Guzmán-Fulgencio; J. Berenguer; M. García-Álvarez; D. Micheloud; J. C. López; J. Cosín; I. Fernández de Castro; P. Catalán; P. Miralles; S. Resino

Publisher
Springer
Year
2011
Tongue
English
Weight
238 KB
Volume
30
Category
Article
ISSN
0934-9723

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Virological and clinical aspects of HBV-
Virological and clinical aspects of HBV-HCV coinfection in HIV positive patients
✍ Pietro Filippini; Nicola Coppola; Raffaella Pisapia; Salvatore Martini; Cecilia 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB

## Abstract In a long‐term follow‐up study the clinical and virological presentation of HBV/HCV coinfection in anti‐HIV positive patients was evaluated. Plasma HBV‐DNA, HCV‐RNA, and HIV‐RNA were determined by PCR in 5 HBsAg/anti‐HCV/anti‐HIV positive patients, in 4 HBsAg/anti‐HIV positive patients

Variations in the serum concentrations o
Variations in the serum concentrations of soluble Fas and soluble Fas ligand in Vietnamese patients infected with hepatitis B virus
✍ Le H. Song; Vu Q. Binh; Dinh N. Duy; Thomas C. Bock; Peter G. Kremsner; Adrian J 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB

## Abstract Earlier studies of both chronic hepatitis B and C virus (HBV and HCV) patients have shown a strong correlation between the soluble membrane Fas (sFas) and Fas protein expression on hepatocytes. The serum concentrations of sFas and soluble Fas ligand (sFasL) was examined in both healthy

Soluble Fas ligand in the joints of pati
Soluble Fas ligand in the joints of patients with rheumatoid arthritis and osteoarthritis
✍ Hideo Hashimoto; Masato Tanaka; Takashi Suda; Tetsuya Tomita; Kenji Hayashida; E 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 718 KB

Objective. To investigate the expression and function of Fas ligand (FasL),which can be in a membranebound or soluble form, in the joints of patients with rheumatoid arthritis (RA) and osteoarthritis (OA). Methods. The concentration of soluble FasL (sFasL) in serum and synovial fluid (SF) from 24 O